Systemic Administration of REOLYSIN® for Patients with Various Metastatic Tumors
In June 2007, Oncolytics announced the final results of its UK Phase I clinical trial investigating the systemic administration of REOLYSIN® in patients with various advanced stage, primary or metastatic tumors who had previously failed all other cancer therapies. The study indicated that REOLYSIN® can be delivered systemically to various tumor types and cause virus-mediated tumor responses. Patients were entered into the trial at a range of dose levels and treated to a maximum daily dose of 1 x 1011 TCID50. A maximum tolerated dose (MTD) was not reached and the treatment appears to have been well tolerated by the patients, with several notable changes in stabilization of disease, as well as some minor tumor regression in patients who had failed all previous treatments.
The primary objective was to determine the safety of REOLYSIN® when administered intravenously. The secondary objective was to observe tumor and immune system response to intravenous infusion of REOLYSIN®, which would help to determine dosage levels in subsequent clinical studies. Patients who derived benefit from the therapy were able to be re-treated at the same dosage at which they were initially treated. The study took place at the Royal Marsden Hospital and St. George's Hospital, both in the United Kingdom.
- November 1, 2008: A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer (PDF)
- June 1, 2007: Oncolytics Biotech Inc.’s Research Collaborators to Present REOLYSIN® Clinical Trial Data at ASCO Conference (Press Release)
- November 9, 2006: Oncolytics Biotech Inc.’s Research Collaborators Present REOLYSIN® Phase I UK Systemic Administration Clinical Trial Results (Press Release)
- June 5, 2006: Oncolytics Biotech Inc. Completes Patient Enrollment in UK Phase I Systemic Administration Clinical Trial (Press Release)
- June 5, 2006: Oncolytics Biotech Inc.’s Research Collaborators Present Positive REOLYSIN® Clinical Trial Data at ASCO Conference (Press Release)